Connect with us

Science

New drug's potentially fatal side effects obscured by 'soothing acronym,' doctors say

Published

on

New drug's potentially fatal side effects obscured by 'soothing acronym,' doctors say

Seventy-nine-year-old Genevieve Lane volunteered to take the Alzheimer’s drug Leqembi in a clinical trial because she was forgetting words and misplacing her keys.

Infusions of the drug gave her headaches so severe they sent her to bed. A week after the third dose, she was at a restaurant with her best friend when her speech slurred and she had a seizure. Five days later she was dead.

An autopsy found that Lane died of a mysterious side effect that has a name that sounds like it might be part of an Italian opera, but has doctors on edge.

The complication called ARIA has nothing to do with music. It is a term adopted by an influential group of pharmaceutical executives and academic scientists to describe potentially fatal bleeding and swelling in the brain caused by drugs like Leqembi.

“Mom believed the drug would help slow progression of her memory problems or do nothing,” said Lane’s daughter, Yvonne Battaglia. “She didn’t know it might kill her.”

Advertisement

Genevieve Lane, 79, of The Villages, Fla., not long before she died in September, 2022. An autopsy blamed Leqembi, a drug for Alzheimer’s disease.

(Lane family)

Lane’s death, and that of two other trial participants, has raised concerns among some doctors, who question whether Leqembi’s risks are worth its benefits, particularly for the population of older adults it was approved for.

Some of these doctors are urging that a new name be given to the drug’s potential side effects to better alert healthcare professionals to its risks.

Advertisement

ARIA is short for “amyloid-related imaging abnormalities,” with imaging referring to the MRI scans needed to find the brain bleeding and swelling.

“Clearly, it is more than just an imaging abnormality,” said Dr. Matthew Schrag, a Vanderbilt University neurologist, who helped with an autopsy that concluded Lane died of brain swelling and bleeding that was likely caused by Leqembi.

“My feeling is that ARIA is too euphemistic of a term. It conveys that this isn’t serious, and it certainly can be,” he said.

Leqembi, known generically as lecanemab, is a monoclonal antibody that works to remove a protein called amyloid from the brain. It received full Food and Drug Administration approval in July.

Eisai, a Japanese drugmaker that has partnered with Biogen, is promoting Leqembi to doctors and people concerned about their memories.

Advertisement

“Get ahead & stay ahead for longer,” an Eisai website says about the drug. It also says that “ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur.”

In a recent article, a Stanford neurologist and his colleagues detailed their concerns about ARIA, which they called a “soothing acronym” for brain bleeding and swelling.

“It does certainly have the ring of something that a pharmaceutical company or public relations person would come up with,” Dr. Michael Greicius said in an interview.

Leqembi is approved for mild dementia and also a diagnosis known as mild cognitive impairment, where patients have more memory problems than others their age but can compensate and continue their daily activities. People with MCI have been found to be at greater risk for developing dementia; but in many cases, their memory problems stay the same or even improve.

The FDA has required that the company warn doctors about ARIA. The agency says the condition, which affected more than 20% of those taking the drug in a large trial, can be managed by requiring patients to get repeated MRI scans to look for bleeding and swelling.

Advertisement

“The FDA maintains that the benefits of Leqembi outweigh its risks when used according to the approved labeling,” said Dr. Teresa Buracchio, director of the FDA’s neuroscience office.

Libby Holman, an Eisai spokesperson, called ARIA “globally established nomenclature.”

Because of the risk of ARIA, some Los Angeles medical centers are taking extra precautions.

At Keck Medicine of USC, a neurologist is available 24/7 to take calls from families of those taking Leqembi, since a headache or sudden confusion can be a sign of ARIA, said Dr. Helena Chui, chair of the neurology department.

At UCLA and Cedars-Sinai Medical Center, warnings pop up in a patient’s electronic health record to ensure that all medical staff know the patient is taking Leqembi, because it can interact with certain other medications to make brain bleeding far worse.

Advertisement

And at all three medical centers it takes more than a single doctor to prescribe the drug. Each patient’s case must be reviewed by a panel of doctors and other staff — similar to how complex cancer cases are evaluated.

“We want to keep safety first,” said Dr. Keith Vossel, UCLA professor of neurology. “This is the most complicated, complex drug that we’ve prescribed in the dementia field.”

Other physicians say they won’t prescribe the drug.

“If there was a medication that worked, I would be the first person to use it,” said Dr. Clifford Sigel, a neurologist in Santa Monica. “But I won’t be using this in my practice.”

He pointed to a large clinical trial of Leqembi that led to its approval. It found that patients who took the drug saw their memory decline 27% more slowly — or less than half a point on an 18-point cognitive scale — than their counterparts who took a placebo. Sigel and other doctors doubt patients or their families would notice the difference.

Advertisement

Eisai’s Holman disputed claims that the drug does not work. She noted that a panel of outside experts convened by the FDA had voted unanimously that trial data confirmed its clinical benefit.

The name ARIA traces to July 2010 when “turmoil ensued” at an international scientific conference that the Alzheimer’s Assn. holds each year, according to an article by two scientists working in the field.

The FDA had proposed that companies testing new anti-amyloid drugs exclude any volunteer from clinical trials who had more than two brain microbleeds, according to an Alzheimer’s Assn. report. The tiny hemorrhages are sometimes found in healthy people and those with Alzheimer’s or other illnesses.

The agency also said it would require any volunteer who experienced a brain microbleed during the clinical trial to cease taking the drug.

The companies and academics working on the trials viewed the new FDA requirements as “excessively restrictive,” said the report by the association, a nonprofit that has become a powerful force in dementia science.

Advertisement

The industry and academic scientists feared the FDA proposal would stall research on the experimental drugs, the report said, and limit their use.

The drug companies asked the association to debate the FDA’s guidance at its Research Roundtable. Pharmaceutical and medical testing companies can become members of the roundtable by paying the association a $50,000 annual fee.

The association said that “one key question” taken up by the roundtable was whether ARIA was a temporary symptom of the new drug — much the way nausea and hair loss are side effects of chemotherapy — or evidence that anti-amyloid medicines may have more serious adverse effects. That question was never settled.

“Current knowledge doesn’t provide definitive answers to this critical question,” the association said in the 2011 report explaining the roundtable’s work.

Despite the unknowns, the roundtable proposed that volunteers be allowed into the trials even if they had as many as four brain microbleeds. The group said volunteers could keep getting the drug infusions if they developed brain bleeding as long as they did not have significant worsening of symptoms such as headaches and confusion.

Advertisement

The roundtable also proposed calling the brain bleeding and swelling ARIA.

The FDA “subsequently revised and updated the original advice…in a manner consistent” with the roundtable’s suggestions, wrote three of its members.

“Scientific evidence at the time led the workgroup to propose excluding people who have four or more microbleeds from clinical trials,” the association told The Times in a statement. “The FDA agreed.”

The association declined to answer questions on whether the name ARIA should be changed.

An FDA official told The Times that the industry group’s advice was just one of the factors the agency considered before it revised its 2010 guidelines.

Advertisement

More than a decade later, little more is known about why ARIA occurs or how to recognize it.

One problem is that a patient with ARIA can look like they’re having a stroke. And when stroke patients are taken to an emergency room, the first treatment doctors often consider is a clot-dissolving medicine called tPA, which can make brain bleeding worse.

That’s what happened to a 65-year-old woman taking Leqembi in a trial who arrived at a Chicago ER with stroke-like symptoms, according to a report published in February 2023. Doctors gave her tPA.

“As soon as they put it in her, it was like her body was on fire,” the woman’s husband said in a news story in the journal Science. “She was screaming, and it took like eight people to hold her down.”

The woman died, and an autopsy showed extensive bleeding in her brain, leading doctors to conclude the combination of the two drugs may have caused her death.

Advertisement

Knowing about that risk, Southern California doctors have been teaching emergency room staff to find out if patients thought to be suffering a stroke may be taking Leqembi.

“We’ve had to train and discuss this with the ER, the neuroradiology team and urgent care,” said Dr. Sarah Kremen, who leads Cedars Sinai’s Alzheimer’s clinical trial program. “You must ask this person, ‘Are you taking this medication?’”

An FDA database that collects reports of adverse drug reactions from doctors and others shows 23 deaths of patients taking Leqembi.

Holman at Eisai said it would be incorrect to assume the deaths were caused by Leqembi. She noted that Alzheimer’s patients have a higher risk of death because of the natural course of the disease.

In the large trial, less than 1% of patients died — the same rate whether they were taking the drug or the placebo.

Advertisement

Buracchio at the FDA said the agency takes “all adverse event reports seriously.” But she said the agency’s evaluation of the reports “must take the treated population into account,” which in this case is typically older or elderly adults.

To teach doctors about ARIA, Eisai created a website called understandingaria.com. It tells doctors that ARIA “usually resolves without intervention or treatment modification.”

In a brochure for healthcare providers, Eisai assures physicians that infusions may continue if an MRI turns up evidence of microbleeds as long as there are four or fewer and that the discomfort doesn’t disrupt the patient’s activities.

For Genevieve Lane, an MRI discovered four brain microbleeds before she started taking Leqembi in the trial.

After Lane died, an autopsy found more than 30 microbleeds in her brain, including some that could not be seen on the MRI, according to a report in Nature Communications.

Advertisement

The report’s authors, who included Schrag at Vanderbilt, questioned whether the pre-treatment limit of four brain microbleeds was stringent enough and called for higher standards.

The FDA told The Times that the agency had reviewed the available data and had not identified a specific number of preexisting microhemorrhages that would make it unsafe for patients to take anti-amyloid drugs like Leqembi.

“However, we will continue to monitor the accruing safety data,” the agency said.

Other doctors have questioned what happens to the memories of those who suffer ARIA, even if the bleeding and swelling appears to resolve.

Dr. Madhav Thambisetty, a senior researcher at the National Institute of Aging, said he was concerned by a report in a French medical journal about two women with mild dementia who experienced serious ARIA during a trial. One suffered severe seizures; 11 months later, her memory score dropped by nine points on a 30-point scale. The other patient developed a brain bleed described as “massive”; she lost a significant part of her vision, and her memory score declined by 12 points on the same scale.

Advertisement

An FDA scientist reviewing reports of patients who suffered high numbers of microbleeds in the clinical trial also noted the possible harm to their cognition in her January 2023 report on Leqembi.

One of the patients that Dr. Deniz Erten-Lyons pointed to was a 68-year-old man who had four microbleeds before starting the infusions. After treatment, he began to lose his vision and was hospitalized because of a seizure. An MRI found 96 microbleeds.

Thambisetty said he and Dr. Rob Howard of University College London wrote to Eisai last year to request information about what happened to the cognition of those who suffered ARIA in trials.

Eisai has not responded to their request, he said.

“I’m concerned about the lack of full and transparent reporting,” Thambisetty said. “It’s really important to know what happens to these patients.”

Advertisement

Holman said the company’s analysis of trial data showed that ARIA did not impact cognition.

“Eisai is transparent,” she said. The company follows guidelines for sharing clinical data established by PhRMA, the industry trade association, Holman said.

Greicius, the Stanford professor, also asked Eisai for trial data that would break down results for each volunteer to better understand ARIA and whether patients benefited as more amyloid was removed from their brains.

The response from Eisai, he said, was, “Thanks for your interest, but we can’t release the data.”

Advertisement

Science

Video: SpaceX’s Starship Has Smooth Launch but Uncontrolled Reentry

Published

on

Video: SpaceX’s Starship Has Smooth Launch but Uncontrolled Reentry

new video loaded: SpaceX’s Starship Has Smooth Launch but Uncontrolled Reentry

transcript

transcript

SpaceX’s Starship Has Smooth Launch but Uncontrolled Reentry

The spacecraft sprang a propellant leak, causing it to break apart and scatter debris in the Indian Ocean.

We did spring a leak in some of the fuel tank systems inside of Starship, which a lot of those are used for your attitude control. Plasma build up during reentry. We do expect the vehicle to see about 1,400 degrees Celsius. And there you can see the flap. At this point, we had lost attitude control of the ship and entered into a spin.

Advertisement

Recent episodes in Science

Continue Reading

Science

Cancer diagnosis and a new book fuel questions about Biden's decision to run in 2024

Published

on

Cancer diagnosis and a new book fuel questions about Biden's decision to run in 2024

The revelation that former President Biden has advanced prostate cancer generated more questions than answers on Monday, prompting debate among experts in the oncology community over the likely progression of his disease and resurfacing concerns in Washington over his decision last year to run for reelection.

Biden’s private office said Sunday afternoon that he had been diagnosed earlier in the week with an “aggressive form” of the cancer that had already spread to his bones, after urinary symptoms led to the discovery of a nodule on his prostate.

But it was not made clear whether Biden, 82, had been testing his prostate-specific antigens, known as PSA levels, during his presidency — and if so whether those results had indicated an elevated risk of cancer while he was still in office or during his campaign for reelection.

Biden’s diagnosis comes at a difficult time for the former president, as scrutiny grows over his decision to run for a second term last year — and whether it cost the Democrats the White House. Biden ultimately dropped out of the race after a devastating debate performance with Donald Trump laid bare widespread concerns over his age and health, leaving his successor on the Democratic ticket — Vice President Kamala Harris — little time to run her own campaign.

A book set to publish this week titled “Original Sin,” by journalists Jake Tapper and Alex Thompson, details efforts by Biden’s aides to shield the effects of his aging from the public and the press. The cancer diagnosis only intensified scrutiny over Biden’s health and questions as to whether he and his team were honest about it with the public.

Advertisement

“I think those conversations are going to happen,” said David Axelrod, a former senior advisor to President Obama.

President Trump, asked about Biden’s diagnosis during an Oval Office event Monday, said it was “a very, very sad situation” and that he felt “badly about it.”

But he also questioned why the cancer wasn’t caught earlier, and why the public wasn’t notified earlier, tying the situation to questions he has long raised about Biden’s mental fitness to serve as president.

PSA tests are not typically recommended for men over 70 due to the risk of false positive results or of associated treatments causing more harm than good to older patients, who are more likely to die of other causes first.

But annual physicals for sitting presidents — especially of Biden’s age — are more comprehensive than those for private citizens. And a failure to test for elevated PSA levels could have missed the progression of the disease.

Advertisement

A letter from Biden’s White House physician from February of last year made no mention of PSA testing, unlike the most recent letter detailing the results of Trump’s latest physical, which references a normal measurement. Biden’s current aides did not respond to requests for comment on whether his office would further detail his diagnostic testing history.

Even if his doctors had tested for PSA levels at the time, results may not have picked up an aggressive form of the cancer, experts said.

Some specialists in the field said it was possible, if rare, for Biden’s cancer to emerge and spread since his last physical in the White House. Roughly 10% of patients who are newly diagnosed with prostate cancer are found with an advanced form of the disease that has metastasized to other parts of the body.

Dr. Mark Litwin, the chair of UCLA Urology, said it is in the nature of aggressive prostate cancers to grow quickly. “So it is likely that this tumor began more recently,” he said.

Litwin said he does not doubt that Biden would have been screened for elevated PSA levels. But, he said, he could be among those patients whose cancers do not produce elevated PSA levels or whose more aggressive cancers rapidly grow and metastasize within a matter of months.

Advertisement

“The fact that he has metastatic disease at diagnosis, to me, as an expert in the area and as a clinician taking care of guys with prostate cancer all the time, just says that he is unfortunate,” Litwin said.

Litwin and other experts in prostate cancer from USC, Stanford, Johns Hopkins, Cedars-Sinai and the Dana-Farber Cancer Institute all told The Times that Biden’s diagnosis — at least based on publicly available information — was not incredibly unusual, and similar to diagnoses received by older American men all the time.

They said he and his doctors absolutely would have discussed testing his PSA levels, given his high level of care as president. But they also said it would have been well within medical best practices for him to decide with those doctors to stop getting tested given his age.

Dr. Howard Sandler, chair of the Department of Radiation Oncology at Cedars-Sinai, said he sees three potential explanations for Biden’s diagnosis.

One is that Biden and his doctors made a decision “to not screen any longer, which would be well within the standard of care” given Biden’s age, he said.

Advertisement

A second is that Biden’s was tested, and his PSA level “was elevated, maybe not dramatically but a little bit elevated, but they said, ‘Well, we’re not gonna really investigate it,’” again because of Biden’s age, Sandler said.

The third, which Sandler said was “less likely,” is that Biden’s PSA was checked “and was fine, but he ended up with an aggressive prostate cancer that doesn’t produce much PSA” and so wasn’t captured.

Zeke Emanuel, an oncologist serving as vice provost for global initiatives at the University of Pennsylvania and a former health policy official in the Biden administration, told MSNBC that Biden has likely had cancer for “more than several years.”

“He did not develop it in the last 100, 200 days. He had it while he was president. He probably had it at the start of his presidency, in 2021,” Emanuel said.

But Litwin, who said he is a friend of Emanuel’s, said most men in their 70s or 80s have some kind of prostate cancer, even if it is just “smoldering along” — there but not particularly aggressive or quickly spreading — and unlikely to be the cause of their death.

Advertisement

He said Biden may well have had some similar form of cancer in his prostate for a long time, but that he did not believe that the aggressive form that has metastasized would have been around for as long as Emanuel seemed to suggest.

Departing Rome aboard Air Force Two, Vice President JD Vance told reporters he was sending his best wishes to the former president, but expressed concern that his recent diagnosis underscored concerns over Biden’s condition that dogged his presidency.

“Whether the right time to have this conversation is now or in the future, we really do need to be honest about whether the former president was capable of doing the job,” Vance said. “I don’t think that he was in good enough health. In some ways, I blame him less than I blame the people around him.”

Trump’s medical team has also faced questions of transparency.

Advertisement

When Trump was diagnosed with COVID-19 during his first term, at the height of the pandemic, he was closer to death than his White House acknowledged at the time. And his doctors and aides regularly use superlatives to describe the health of the 78-year-old president, with Karoline Leavitt, his White House press secretary, referring to him as “perfect” on Monday.

“Cancer touches us all,” Biden posted on social media alongside a photo with his wife, Jill Biden, in his first remarks on his diagnosis.

“Like so many of you, Jill and I have learned that we are strongest in the broken places,” he added. “Thank you for lifting us up with love and support.”

Advertisement
Continue Reading

Science

A mysterious, highly active undersea volcano near California could erupt later this year. What scientists expect

Published

on

A mysterious, highly active undersea volcano near California could erupt later this year. What scientists expect

• Axial Seamount is the best-monitored submarine volcano in the world.
• It’s the most active undersea volcano closest to California.
• It could erupt by the end of the year.

A mysterious and highly active undersea volcano off the Pacific Coast could erupt by the end of this year, scientists say.

Nearly a mile deep and about 700 miles northwest of San Francisco, the volcano known as Axial Seamount is drawing increasing scrutiny from scientists who only discovered its existence in the 1980s.

Located in a darkened part of the northeast Pacific Ocean, the submarine volcano has erupted three times since its discovery — in 1998, 2011 and 2015 — according to Bill Chadwick, a research associate at Oregon State University and an expert on the volcano.

Fortunately for residents of California, Oregon and Washington, Axial Seamount doesn’t erupt explosively, so it poses zero risk of any tsunami.

Advertisement

“Mt. St. Helens, Mt. Rainier, Mt. Hood, Crater Lake — those kind of volcanoes have a lot more gas and are more explosive in general. The magma is more viscous,” Chadwick said. “Axial is more like the volcanoes in Hawaii and Iceland … less gas, the lava is very fluid, so the gas can get out without exploding.”

The destructive force of explosive eruptions is legendary: when Mt. Vesuvius blew in 79 AD, it wiped out the ancient Roman city of Pompeii; when Mt. St. Helens erupted in 1980, 57 people died; and when the Hunga Tonga-Hunga Haʻapai volcano in Tonga’s archipelago exploded in 2022 — a once-in-a-century event — the resulting tsunami, which reached a maximum height of 72 feet, caused damage across the Pacific Ocean and left at least six dead.

Axial Seamount, by contrast, is a volcano that, during eruptions, oozes lava — similar to the type of eruptions in Kilauea on the Big Island of Hawaii. As a result, Axial’s eruptions are not noticeable to people on land.

It’s a very different story underwater.

Heat plumes from the eruption will rise from the seafloor — perhaps half a mile — but won’t reach the surface, said William Wilcock, professor of oceanography at the University of Washington.

Advertisement

Jason is a remotely operated vehicle (ROV) system designed to allow scientists to have access to the seafloor without leaving the ship.

(Dave Caress/MBARI)

The outermost layer of the lava flow will almost immediately cool and form a crust, but the interior of the lava flow can remain molten for a time, Chadwick said. “In some places … the lava comes out slower and piles up, and then there’s all this heat that takes a long time to dissipate. And on those thick flows, microbial mats can grow, and it almost looks like snow over a landscape.”

Sea life can die if buried by the lava, which also risks destroying or damaging scientific equipment installed around the volcano to detect eruptions and earthquakes. But the eruption probably won’t affect sea life such as whales, which are “too close to the surface” to be bothered by the eruption, Wilcock said.

Advertisement

Also, eruptions at Axial Seamount aren’t expected to trigger a long-feared magnitude 9.0 earthquake on the Cascadia subduction zone. Such an earthquake would probably spawn a catastrophic tsunami for Washington, Oregon and California’s northernmost coastal counties. That’s because Axial Seamount is located too far away from that major fault.

Axial Seamount is one of countless volcanoes that are underwater. Scientists estimate that 80% of Earth’s volcanic output — magma and lava — occurs in the ocean.

Axial Seamount has drawn intense interest from scientists. It is now the best-monitored underwater volcano in the world.

The volcano is a prolific erupter in part because of its location, Chadwick said. Not only is it perched on a ridge where the Juan de Fuca and Pacific tectonic plates spread apart from each other — creating new seafloor in the process — but the volcano is also planted firmly above a geological “hot spot” — a region where plumes of superheated magma rise toward the Earth’s surface.

For Chadwick and other researchers, frequent eruptions offer the tantalizing opportunity to predict volcanic eruptions weeks to months in advance — something that’s very difficult to do with other volcanoes. (There’s also much less likelihood anyone will get mad if scientists get it wrong.)

3D image of Axial Seamount volcano

A three-dimensional topographic depiction showing the summit caldera of Axial Seamount, a highly active undersea volcano off the Pacific Coast. Warmer colors indicate shallower surfaces; cooler colors indicate deeper surfaces.

(Susan Merle / Oregon State University)

Advertisement

“For a lot of volcanoes around the world, they sit around and are dormant for long periods of time, and then suddenly they get active. But this one is pretty active all the time, at least in the time period we’ve been studying it,” Chadwick said. “If it’s not erupting, it’s getting ready for the next one.”

Scientists know this because they’ve spotted a pattern.

“Between eruptions, the volcano slowly inflates — which means the seafloor rises. … And then during an eruption, it will, when the magma comes out, the volcano deflates and the seafloor drops down,” Wilcock said.

Eruptions, Chadwick said, are “like letting some air out of the balloon. And what we’ve seen is that it has inflated to a similar level each time when an eruption is triggered,” he said.

Advertisement

Chadwick and fellow scientist Scott Nooner predicted the volcano’s 2015 eruption seven months before it happened after they realized the seafloor was inflating quite quickly and linearly. That “made it easier to extrapolate into the future to get up to this threshold that it had reached before” eruption, Chadwick said.

But making predictions since then has been more challenging. Chadwick started making forecast windows in 2019, but around that time, the rate of inflation started slowing down, and by the summer of 2023, “it had almost stopped. So then it was like, ‘Who knows when it’s going to erupt?’”

A deep-sea octopus explores the lava flows four months after the Axial Seamount volcano erupted in 2015.

A deep-sea octopus explores the lava flows four months after the Axial Seamount volcano erupted in 2015.

(Bill Chadwick, Oregon State University / Woods Hole Oceanographic Institution / National Science Foundation)

But in late 2023, the seafloor slowly began inflating again. Since the start of 2024, “it’s been kind of cranking along at a pretty steady rate,” he said. He and Nooner, of the University of North Carolina at Wilmington, made the latest eruption prediction in July 2024 and posted it to their blog. Their forecast remains unchanged.

Advertisement

“At the rate of inflation it’s going, I expect it to erupt by the end of the year,” Chadwick said.

But based on seismic data, it’s not likely the volcano is about to erupt imminently. While scientists haven’t mastered predicting volcanic eruptions weeks or months ahead of time, they do a decent job of forecasting eruptions minutes to hours to days ahead of time, using clues like an increased frequency of earthquakes.

At this point, “we’re not at the high rate of seismicity that we saw before 2015,” Chadwick said. “It wouldn’t shock me if it erupted tomorrow, but I’m thinking that it’s not going to be anytime soon on the whole.”

He cautioned that his forecast still amounts to an experiment, albeit one that has become quite public. “I feel like it’s more honest that way, instead of doing it in retrospect,” Chadwick said in a presentation in November. The forecast started to garner attention after he gave a talk at the American Geophysical Union meeting in December.

On the bright side, he said, “there’s no problem of having a false alarm or being wrong,” because the predictions won’t affect people on land.

Advertisement

If the predictions are correct, “maybe there’s lessons that can be applied to other more hazardous volcanoes around the world,” Chadwick said. As it stands now, though, making forecasts for eruptions for many volcanoes on land “are just more complicated,” without having a “repeatable pattern like we’re seeing at this one offshore.”

Scientists elsewhere have looked at other ways to forecast undersea eruptions. Scientists began noticing a repeatable pattern in the rising temperature of hydrothermal vents at a volcano in the East Pacific and the timing of three eruptions in the same spot over the last three decades. “And it sort of worked,” Chadwick said.

Plenty of luck allowed scientists to photograph the eruption of the volcanic site known as “9 degrees 50 minutes North on the East Pacific Rise,” which was just the third time scientists had ever captured images of active undersea volcanism.

But Chadwick doubts researchers will be fortunate enough to videotape Axial Seamount’s eruption.

Although scientists will be alerted to it by the National Science Foundation-funded Ocean Observatories Initiative Regional Cabled Array — a sensor system operated by the University of Washington — getting there in time will be a challenge.

Advertisement

“You have to be in the right place at the right time to catch an eruption in action, because they don’t last very long. The ones at Axial probably last a week or a month,” Chadwick said.

And then there’s the difficulty of getting a ship and a remotely operated vehicle or submarine to capture the images. Such vessels are generally scheduled far in advance, perhaps a year or a year and a half out, and projects are tightly scheduled.

Chadwick last went to the volcano in 2024 and is expected to go out next in the summer of 2026. If his predictions are correct, Axial Seamount will have already erupted.

Advertisement
Continue Reading
Advertisement

Trending